Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Cipla
Accenture
McKinsey
McKesson
Medtronic
Mallinckrodt
UBS
Cerilliant
Fuji

Generated: October 24, 2017

DrugPatentWatch Database Preview

Sucampo Pharma Llc Company Profile

« Back to Dashboard

What is the competitive landscape for SUCAMPO PHARMA LLC, and when can generic versions of SUCAMPO PHARMA LLC drugs launch?

SUCAMPO PHARMA LLC has two approved drugs.

There are eighteen US patents protecting SUCAMPO PHARMA LLC drugs.

There are two hundred and twelve patent family members on SUCAMPO PHARMA LLC drugs in twenty-eight countries and eight supplementary protection certificates in six countries.

Summary for Applicant: Sucampo Pharma Llc

International Patents:212
US Patents:18
Tradenames:2
Ingredients:2
NDAs:2
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sucampo Pharma Llc
AMITIZA
lubiprostone
CAPSULE;ORAL021908-002Apr 29, 2008RXYesNo► Subscribe► SubscribeY ► Subscribe
Sucampo Pharma Llc
RESCULA
unoprostone isopropyl
SOLUTION/DROPS;OPHTHALMIC021214-001Aug 3, 2000DISCNYesNo► Subscribe► SubscribeY ► Subscribe
Sucampo Pharma Llc
AMITIZA
lubiprostone
CAPSULE;ORAL021908-002Apr 29, 2008RXYesNo► Subscribe► SubscribeY ► Subscribe
Sucampo Pharma Llc
AMITIZA
lubiprostone
CAPSULE;ORAL021908-001Jan 31, 2006RXYesYes► Subscribe► Subscribe ► Subscribe
Sucampo Pharma Llc
AMITIZA
lubiprostone
CAPSULE;ORAL021908-002Apr 29, 2008RXYesNo► Subscribe► Subscribe ► Subscribe
Sucampo Pharma Llc
AMITIZA
lubiprostone
CAPSULE;ORAL021908-002Apr 29, 2008RXYesNo► Subscribe► SubscribeY ► Subscribe
Sucampo Pharma Llc
AMITIZA
lubiprostone
CAPSULE;ORAL021908-001Jan 31, 2006RXYesYes► Subscribe► SubscribeY ► Subscribe
Sucampo Pharma Llc
AMITIZA
lubiprostone
CAPSULE;ORAL021908-002Apr 29, 2008RXYesNo► Subscribe► Subscribe ► Subscribe
Sucampo Pharma Llc
AMITIZA
lubiprostone
CAPSULE;ORAL021908-002Apr 29, 2008RXYesNo► Subscribe► SubscribeY ► Subscribe
Sucampo Pharma Llc
AMITIZA
lubiprostone
CAPSULE;ORAL021908-002Apr 29, 2008RXYesNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Sucampo Pharma Llc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sucampo Pharma Llc
RESCULA
unoprostone isopropyl
SOLUTION/DROPS;OPHTHALMIC021214-001Aug 3, 2000► Subscribe► Subscribe
Sucampo Pharma Llc
AMITIZA
lubiprostone
CAPSULE;ORAL021908-001Jan 31, 2006► Subscribe► Subscribe
Sucampo Pharma Llc
RESCULA
unoprostone isopropyl
SOLUTION/DROPS;OPHTHALMIC021214-001Aug 3, 2000► Subscribe► Subscribe
Sucampo Pharma Llc
AMITIZA
lubiprostone
CAPSULE;ORAL021908-002Apr 29, 2008► Subscribe► Subscribe
Sucampo Pharma Llc
RESCULA
unoprostone isopropyl
SOLUTION/DROPS;OPHTHALMIC021214-001Aug 3, 2000► Subscribe► Subscribe
Sucampo Pharma Llc
AMITIZA
lubiprostone
CAPSULE;ORAL021908-001Jan 31, 2006► Subscribe► Subscribe
Sucampo Pharma Llc
RESCULA
unoprostone isopropyl
SOLUTION/DROPS;OPHTHALMIC021214-001Aug 3, 2000► Subscribe► Subscribe
Sucampo Pharma Llc
RESCULA
unoprostone isopropyl
SOLUTION/DROPS;OPHTHALMIC021214-001Aug 3, 2000► Subscribe► Subscribe
Sucampo Pharma Llc
RESCULA
unoprostone isopropyl
SOLUTION/DROPS;OPHTHALMIC021214-001Aug 3, 2000► Subscribe► Subscribe
Sucampo Pharma Llc
AMITIZA
lubiprostone
CAPSULE;ORAL021908-002Apr 29, 2008► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for SUCAMPO PHARMA LLC drugs

Drugname Dosage Strength Tradename Submissiondate
unoprostone isopropyl
Ophthalmic Solution0.15%
RESCULA
5/12/2014
lubiprostone
Capsules8 mcg and 24 mcg
AMITIZA
8/20/2012

Non-Orange Book Patents for Sucampo Pharma Llc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,610,732 Anti-constipation composition► Subscribe
7,371,069Manikin and eye device apparatus, methods and articles of manufacture► Subscribe
7,253,295Chloride channel opener► Subscribe
6,923,654 Manikin and eye device apparatus, methods and articles of manufacture► Subscribe
8,748,454Anti-constipation composition► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Sucampo Pharma Llc Drugs

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)03041716► Subscribe
Portugal2298314► Subscribe
Czech Republic20023092► Subscribe
Brazil0109192► Subscribe
European Patent Office2281564► Subscribe
Canada2419741► Subscribe
Israel192867► Subscribe
China1379769► Subscribe
Argentina104392► Subscribe
Russian Federation2008134489► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Sucampo Pharma Llc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0757Netherlands► SubscribePRODUCT NAME: LUBIPROSTON; NATIONAL REGISTRATION NO/DATE: RVG 115891; FIRST REGISTRATION NO/DATE: PL21341/0003 20120910
1315485/01Switzerland► SubscribeFORMER REPRESENTATIVE: BOHEST AG, CH
826Luxembourg► SubscribePRODUCT NAME: LUBIPROSTONE, INCLUANT LES SELS PHARMACEUTIQUEMENT ACCEPTABLES, LES ESTERS OU LES AMIDES DE LA LUBIPROSTONE. FIRST REGISTRATION: 20120910
2015000080Germany► SubscribePRODUCT NAME: LUBIPROSTON, ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; NAT. REGISTRATION NO/DATE: 92699.00.00 20150519; FIRST REGISTRATION: VEREINIGTES KOENIGREICH PL 21341/0003 20120910
00757Netherlands► SubscribePRODUCT NAME: LUBIPROSTON; NAT. REGISTRATION NO/DATE: RVG 115891 20150317; FIRST REGISTRATION:
/2015Austria► SubscribePRODUCT NAME: LUBIPROSTON UND PHARMAZEUTISCH ANNEHMBARE SALZE DAVON; NAT. REGISTRATION NO/DATE: 136176 20150508; FIRST REGISTRATION: GB PL 21341/0003 20120910
00135Netherlands► SubscribePRODUCT NAME: UNOPROSTONEZUUR, DESGEWENST IN DE VORM VAN EEN ESTER OF EEN ZOUT; NATL REGISTRATION NO/DATE: RVG 28628 20030708; FIRST REGISTRATION: FR 359 911-5 AND 359 912-1 20020917
15/028Ireland► SubscribePRODUCT NAME: LUBIPROSTONE AND PHARMACEUTICALLY ACCEPTABLE SALTS FOR LUBIPROSTONE.; NAT REGISTRATION NO/DATE: PA148/002/001 20150213; FIRST REGISTRATION NO/DATE: PL21341/0003-0001 20120910
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Cipla
Boehringer Ingelheim
Dow
Citi
Colorcon
Covington
Julphar
Deloitte
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot